Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%. Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (LSE:0A3L) from Outperform to Market Perform. There are 474 funds or institutions reporting positions in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings throughout the application software sector at the start of 2025.

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

NASDAQ:VERX opened at $51.32 on Friday. The firm has a 50-day simple moving average of $51.64 and a two-hundred day simple moving average of $42.49. The firm has a market cap of $8.00 billion, a P ...

Vertex, Inc. (NASDAQ:VERX – Free Report) – DA Davidson issued their FY2024 earnings per share (EPS) estimates for shares of Vertex in a report released on Tuesday, December 31st.DA Davidson ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...